
Evan Feinberg, CEO of Genesis Therapeutics (Boris Feldman)
Genentech-partnered Genesis Therapeutics inks newest AI discovery deal with Eli Lilly
A Stanford biotech rubbed elbows with Genentech in 2020, reaching a deal with the big-name biotech just over 18 months ago. And now, the AI outfit is in its second partnership with Big Pharma.
Genesis Therapeutics secured a deal with big pharma Eli Lilly, the company announced on Tuesday — to discover therapies “across a range of therapeutic areas,” according to a statement put out by the biotech.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters